GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
Tweet Send to a Friend
Canaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
